Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting

We evaluated the efficacy and safety of trifluridine/tipiracil (TAS-102) plus bevacizumab in treating refractory metastatic colorectal cancer (mCRC) in a retrospective, observational study. Patients refractory or intolerant to standard therapies received TAS-102 (30–35 mg/m(2) twice daily on days 1–...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Lago, Nieves, Chucla, Teresa Calleja, De Castro, Beatriz Alonso, Ponte, Rafael Varela, Rendo, Cristina Reboredo, Rodriguez, Martin Igor Gomez-Randulfe, Diaz, Sofia Silva, Suarez, Begoña Graña, de la Cámara Gomez, Juan, Fernández, Fernando Busto, Salvador, María Mateos, Lopez, Margarita Reboredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418211/
https://www.ncbi.nlm.nih.gov/pubmed/36028552
http://dx.doi.org/10.1038/s41598-022-18871-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418211/
https://www.ncbi.nlm.nih.gov/pubmed/36028552
http://dx.doi.org/10.1038/s41598-022-18871-9

Ejemplares similares